Immutep Limited

Immutep Limited is a biotechnology company that engages in the research and development of pharmaceutical product candidates for the treatment of cancer and autoimmune diseases. The company’s lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is currently in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. In addition, Immutep Limited is also developing TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. The company’s other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity.

Immutep Limited has a number of collaborations with other pharmaceutical companies, including GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was founded in 1987 and is based in Sydney, Australia. Immutep Limited is listed on the Australian Securities Exchange (ASX) and is a publicly traded company. The company has a market capitalization of approximately $100 million and is a member of the S&P/ASX 200 index. Immutep Limited has a highly experienced management team and a strong focus on research and development, which has enabled the company to develop some promising products for the treatment of cancer and autoimmune diseases.